• LAST PRICE
    223.5000
  • TODAY'S CHANGE (%)
    Trending Up0.2100 (0.0940%)
  • Bid / Lots
    222.7400/ 4
  • Ask / Lots
    224.6000/ 4
  • Open / Previous Close
    220.5000 / 223.2900
  • Day Range
    Low 219.3900
    High 223.6300
  • 52 Week Range
    Low 119.7604
    High 299.9800
  • Volume
    32,876
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Tuesday's close: 223.29
TimeVolumeMDGL
09:32 ET2063220.595
09:34 ET100219.9
09:39 ET100222.84
09:41 ET300220.29
09:43 ET600219.99
09:45 ET300219.84
09:52 ET300220.455
09:54 ET200221.64
09:56 ET529221.72
09:59 ET1400221.485
10:01 ET2200221.755
10:03 ET100221.775
10:12 ET200222.155
10:14 ET100221.86
10:17 ET271221.06
10:19 ET205220.86
10:21 ET650220.2
10:24 ET1905219.935
10:26 ET601220.495
10:28 ET160221.105
10:32 ET209220.7
10:33 ET1030220.46
10:35 ET499221.45
10:37 ET1700221.99
10:39 ET160222.0407
10:42 ET150221.665
10:46 ET600222.385
10:48 ET200222.61
10:50 ET100222.965
10:53 ET100223.63
11:00 ET300223.5
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesMDGL
Madrigal Pharmaceuticals Inc
4.8B
-9.7x
---
United StatesIBRX
Immunitybio Inc
4.6B
-6.1x
---
United StatesNUVL
Nuvalent Inc
4.3B
-27.2x
---
United StatesBBIO
BridgeBio Pharma Inc
5.2B
-8.5x
---
United StatesKRYS
Krystal Biotech Inc
4.5B
82.9x
---
United StatesIMVT
Immunovant Inc
4.1B
-16.7x
---
As of 2024-05-29

Company Information

Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The Company's product candidate, resmetirom, is a once-daily, oral, liver-directed thyroid hormone receptor-β (THR-β) agonist designed to target key underlying causes of NASH. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). The Company’s clinical development program includes MAESTRO-NASH, MAESTRO-NAFLD-1, and MAESTRO-NASH OUTCOMES.

Contact Information

Headquarters
200 Barr Harbor Dr Ste 400WEST CONSHOHOCKEN, PA, United States 19428-2978
Phone
404-380-9263
Fax
302-655-5049

Executives

Independent Chairman of the Board
Julian Baker
President, Chief Executive Officer, Director
Bill Sibold
Chief Financial Officer, Senior Vice President
Mardi Dier
President of Research and Development, Chief Medical Officer, Director
Rebecca Taub
Senior Vice President, General Counsel
Brian Lynch

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$4.8B
Revenue (TTM)
$0.00
Shares Outstanding
21.3M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
-0.42
EPS
$-23.08
Book Value
$20.39
P/E Ratio
-9.7x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.